LIXTE BIOTECHNOLOGY HOLDINGS Business Summary

Lixte Biotechnology Holdings, Inc. (LIXT) is a clinical-stage pharmaceutical and med-tech company that operates through a dual-pillar business model focused on drug development and advanced radiotherapy. The company primarily generates value through its proprietary Protein Phosphatase 2A (PP2A) inhibitor platform, led by the first-in-class compound LB-100, which utilizes an "activation lethality" mechanism to enhance the efficacy of existing chemotherapy and immunotherapy regimens. Following the November 2025 acquisition of Liora Technologies Europe Ltd., Lixte has expanded into the med-tech sector with the LiGHT System, an electronically controlled proton therapy platform. This strategic pivot aims to transition the company from a purely clinical-stage drug developer toward a recurring revenue model tied to the operation of specialized treatment centers. Lixte competes in the oncology space against firms such as Genelux (GNLX), Oncolytics Biotech (ONCY), and Artiva Biotherapeutics (ARTV), distinguishing itself by targeting the PP2A enzyme—a biological pathway previously considered too toxic for therapeutic intervention. Originally founded in 2005 by the late Dr. John S. Kovach, a former Director of the Mayo Clinic Cancer Center, the company is currently led by Chairman and CEO Geordan Pursglove, an executive with a background in M&A and capital markets who previously served as CEO of Beyond Commerce. The leadership team includes Chief Scientific Officer Bas van der Baan, a veteran of precision oncology from Agendia, and Chief Financial Officer Peter Stazzone, a CPA with over 25 years of experience in high-growth financial operations. In February 2026, the company further strengthened its med-tech division by appointing Sidney Braun, a veteran healthcare strategist, as CEO of its Liora subsidiary. Lixte’s board of directors features notable industry figures including Jason Sawyer of Access Alternative Group, Lourdes Felix of BioCorRx, and Guy Primus, a former executive at Starbucks and Microsoft, providing a diverse pedigree of expertise across biotechnology, finance, and technology-driven innovation.